The EMvision (ASX:EMV) share price jumped today. Here's why

The EMVision (ASX: EMV) share price was on the rise today following news of two technology breakthrough from the company. Here's the lowdown.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

EMVision Medical Devices Ltd (ASX: EMV) shares were on the rise today following news of two significant technology and product development breakthroughs from the company.

By the market's close, the EMVision share price was trading at $3.16, up 4.29% from yesterday's closing price of $3.03.

Let's take a closer look at the latest news from EMVision.

What's driving the EMVision share price?

EMVision shares responded positively today after the company announced it has developed two new technologies. These will work alongside its prototype portable electromagnetic (EM) imaging device, currently being developed as a brain scanner.

The EM imaging device differs from other imaging technology currently available as it releases both electric and magnetic fields from its antenna which interact with brain tissue to produce an image. It has the potential to provide clinicians with diagnostic information in a non-invasive, radiation-free manner. 

EMVision states its two latest techniques have the potential to improve stroke diagnosis and care.

Once developed, the company hopes the two breakthroughs announced today can be accessed through its EM imaging device.

Dielectric mapping

The first of these breakthroughs is dielectric mapping. Dielectric mapping may be able to provide clinicians with anatomical detail to help them assess the impact of a stroke.

The company hopes dielectric mapping technology can be used as an alternative to MRI or CT imaging in the future. It states this could be particularly beneficial in situations when traditional imaging techniques are unable to be used, such as in ambulances or in a patient's home.

According to EMVision, its dielectric maps have been produced from data acquired by the company's prototype brain scanner.

Pulsatility

The second breakthrough announced by EMVision today is pulsatility. The company states pulsatility could potentially assist in the diagnosis of large vessel occlusion (LVO) for ischaemic strokes. LVO strokes are caused by a blockage to one of the major arteries in the brain. Early diagnosis and treatment of LVO strokes can have a significant impact on a patient's outcome. 

EMVision states that pulsatility technology could help reduce treatment delays and, therefore, the occurrence of resulting disability in patients. The technology could also minimise healthcare, insurer, and societal costs.

According to EMVision , since the technology has the potential to measure blood flow through the brain, it could help identify the degree of a blockage at its earliest stages. It could also help to localise any salvageable tissue and begin treatments to restore blood flow.

Expert commentary

Australian Stroke Alliance co-chair Professor Stephen Davis commented in the company's release, saying:

We hope that further advances in this technology will allow treatment of patients in rural and remote locations in Australia who would otherwise remain untreated.

Based on the very promising data from EMVision, we are engaged in preparing for multi-site clinical trials and it is hoped this will lead to future widespread application of this technology.

Management commentary

EMVision CEO Dr Ron Weinberger commented on the company's breakthroughs, stating:

The dielectric maps will have a dramatic impact on the interpretation of data from our algorithms. For the first time using EM imaging, clinicians will be able to make good approximations to the anatomical region at which stroke occurs and will enable a visualisation of the EM image for clinicians that is familiar to them and what they have been looking at for decades [using] CT and MRI…

 Pulsatility is a complimentary technique that alongside our existing diagnostic algorithms, has the potential to improve diagnosis and treatment and save more lives.

EMVision share price snapshot

Today's news comes at a good time for EMVision shares as they've had a lacklustre performance on the ASX so far this year.

Following today's boost, the EMVision share price is now up by 1.94% year to date. The company's shares are, however, up by 295% over the last 12 months.

EMVision has a market capitalisation of around $214 million, with approximately 70 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »